Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 19M | 13M | 3M | 7M | 16M |
| Gross Profit | 11M | 6M | -2M | -5M | 449K |
| Operating Income | 1M | -1M | -13M | -17M | -16M |
| EBITDA | 1M | -310K | -1M | -8M | -24M |
| Net Income | -8M | -3M | 6M | -18M | -48M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rennova Health, Inc. (RNVA) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +43.3%, EPS growth of +99.4%, a dividend yield of 0.0%. What stands out right now is revenue +43.3%, EPS +99.4%, free cash flow +1297.6% with operating margin 7.3% and ROIC -7.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RNVA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNVA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNVA Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNVA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$16.0M
+122.3% YoY
FY Net Income
-$48.0M
-161.9% YoY
Free Cash Flow
-$13.5M
+21.8% YoY
Revenue Growth
+43.3%
EPS Growth
+99.4%
Gross Margin
59.5%
Net Margin
-41.4%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 19M | 13M | 3M | 7M | 16M |
| Gross Profit | 11M | 6M | -2M | -5M | 449K |
| Operating Income | 1M | -1M | -13M | -17M | -16M |
| EBITDA | 1M | -310K | -1M | -8M | -24M |
| Net Income | -8M | -3M | 6M | -18M | -48M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49K | 499K | 725K | 25K | 17K |
| Total Assets | 20M | 21M | 20M | 12M | 15M |
| Total Liabilities | 57M | 50M | 47M | 61M | 84M |
| Shareholder Equity | -37M | -29M | -27M | -49M | -69M |
| Total Debt | 12M | 15M | 16M | 22M | 50M |
| Net Debt | 12M | 15M | 15M | 22M | 50M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14M
+20.1% YoY
Capital Expenditures
125
+100.0% YoY
Free Cash Flow
14M
+21.8% YoY
Key ratios
Gross Margin
59.5%
Operating Margin
7.3%
Net Margin
-41.4%
ROE
23.5%
Debt / Equity
-0.32x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.